Delcath Systems (DCTH) said Tuesday that five new clinical trial sites in the U.S. have been activated in the company’s global Focus phase 3 clinical trial for patients with hepatic dominant ocular melanoma. This brings the total to 8 cancer centers in the U.S. for patient enrollment in the Focus trial.

These new centers are at Ohio State University, the MD Anderson Cancer Center, Thomas Jefferson University, University of Chicago and at the University of Maryland.

The Focus trial is a global Phase 3 clinical study evaluating the safety, efficacy and pharmacokinetic profile of Delcath’s Melphalan/HDS system versus best alternative care in 240 patients with ocular melanoma liver metastases.

Shares are up more than 2% at $2.74, still near its all time low of $2.41. The stock has a 52-week high of $10.88.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.